Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The revenue contribution is modest but strategically significant for Kamada’s plasma supply chain and third-party sales growth.
KMDA drugs
KMDA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 26 $8.22entry
- T+1 · 8mo ago −0.85%α +0.83% · $8.15
- T+5 · 8mo ago +3.04%α +1.41% · $8.47
- T+20 · 7mo ago +0.73%α −9.94% · $8.28
- T+60 · 5mo ago −14.48%α −28.43% · $7.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal source plasma. The facility has an annual capacity of 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting growth in specialty plasma collection and third-party plasma sales.
Key Financial Metrics
Key Facts
- FDA approved Kamada's San Antonio plasma collection center following a February 2026 inspection.
- Facility has 50 donor beds and can collect up to 50,000 liters of plasma annually.
- Expected annual revenue contribution of $8M–$10M from normal source plasma sales at full capacity.
- San Antonio center is one of three FDA-approved U.S. plasma centers, alongside Houston and Beaumont.
- Kamada plans to seek EMA approval for the San Antonio site following FDA clearance.
Financial Impact
Adds $8M–$10M in annual revenue at full capacity from plasma sales
Risk Factors
- Revenue projections are forward-looking and dependent on achieving full collection capacity.
- Geopolitical risks in the Middle East could disrupt operations in Israel, affecting overall business stability.
- Regulatory delays possible for EMA approval of the San Antonio center.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262840 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers